Cargando…
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer
There are few approved drugs available for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) and none have been approved in the twenty-first century. Four drugs; thiotepa in 1959, BCG Tice in 1989, BCG Connaught in 1990, and valrubicin in 1998, have been approved for the trea...
Autores principales: | Jarow, Jonathan, Maher, V. Ellen, Tang, Shenghui, Ibrahim, Amna, Kim, Geoffrey, Sridhara, Rajeshwari, Pazdur, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832566/ https://www.ncbi.nlm.nih.gov/pubmed/27088122 http://dx.doi.org/10.3233/BLC-150016 |
Ejemplares similares
-
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
por: Xu, James Xunhai, et al.
Publicado: (2017) -
Minoxidil Topical Foam: A New Kid on the Block
por: Gogtay, Jaideep A, et al.
Publicado: (2009) -
Bexarotene Gel: A New Topical Therapy for Alopecia Areata
por: Rajiv, Mahajan, et al.
Publicado: (2010) -
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018) -
A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris
por: Lu, Liming, et al.
Publicado: (2016)